ATAI Life Sciences NV (ATAI) Quote

It's close!

Im thinking it all begins by the end of June

JUNE 17th Prof. John Marsden (King’s College London) and Dr. Anya Ermakova (Beckley Psytech) will be sharing novel clinical and micro-phenomenological data from our Phase IIa study of BPL-003 for Alcohol Use Disorder at the 2025 CPDD Annual Meeting.

🔗 Learn more: https://t.co/72xtUK1mbx pic.twitter.com/iH35IILLbA— Beckley Psytech (@BeckleyPsytech) June 13, 2025

I like the sound of that!!

Compass pathways announcing 6 new jobs 2 weeks prior to ph3 data readout.. interesting 🤔🚀

https://compasspathways.com/join-us/#careers

"Senior Manager, Packaging and Serialisation"

ATAI owns a portion of CMPS

Lol! Just popped up on StockTwits

Cannot wait for this run to get underway. Always a fun ride.

If I Remember? Pepperidge Farms remembers...

Have you ever seen a ceo so Genuinely excited and thoroughly Passionate about his product and company?

I mean besides Steve Balmer and Microsoft... if you remember that! 😅

Link for those who want to listen in:

Today at 12PM EST

#AlphaNooner – Christian Angermayer on Biotech, Bitcoin, and the Future of Mental Health $ATAI



Psychedelic biotech is entering a new phase and few investors have been earlier or more influential than Christian Angermayer. In this #AlphaNooner, we will cover why the sector is gaining real traction, what’s driving renewed institutional interest, and how $ATAI is positioned with multiple Phase 2 trials and strong financial runway. Essential viewing for investors watching the next frontier in mental health treatment.

Tune in for the AlphaNooner, Daily at 12:00 pm ET
Each weekday at 12:00 pm ET, join us live for the AdvisorShares AlphaNooner show (#alphanooner) where we discuss timely topics with experts.

Ready to listen... it's go time.

Christian is live on podcast at noon eastern time TODAY!

#AlphaNooner LIVE TODAY at 12PM ET! Join Christian Angermayer @C_Angermayer, founder of Apeiron Investment Group, and host Mackenzie Peterson @mpadvisorshares, talking psychedelic renaissance and biotech breakthroughs.#Psychedelics #Investing #Biotech $ATAI pic.twitter.com/s2PW1qHGDX— AdvisorShares (@AdvisorShares) June 9, 2025

Trump administration exploring potential benefits of psychedelic treatments

Fox News correspondent Alexandria Hoff discusses the Trump administration’s stances on psychedelic treatments on ‘America’s Newsroom.’

https://www.foxnews.com/video/6373914669112

Those targets were with them alone, this will change the game!

I feel that most analysts target prices are way too low and they will continue to get adjusted Upward!

I like the sound of that and I agree 👍 💯🔥

Strong sentiment at the @Jefferies Healthcare Conference in NYC. Investors are waking up to how cheap #biotech is. FDA's @MartyMakary gave a bullish fireside chat. With macro shifts and rate cuts ahead - I’m calling the bottom. Biotech is back. 🚀

Strong sentiment at the @Jefferies Healthcare Conference in NYC. Investors are waking up to how cheap #biotech is. FDA's @MartyMakary gave a bullish fireside chat. With macro shifts and rate cuts ahead - I’m calling the bottom. Biotech is back. 🚀 https://t.co/W2Pb20ZiFy— Christian Angermayer (@C_Angermayer) June 5, 2025

This is going to 15.00 between now and the end of the year.

NeuroGram+

Taking A Break from The Festival of Fools
It might seem a shallow and all-too-brief flight from the daily tawdry display of malevolent incompetence, but the past couple months have offered an occasional glimmer of solid work yielding the hope of better things to come. May 27 was one of those welcome moments: It was a day that saw Neurvati/GRIN announce both a healthy Series D and a European partner; Syneido came up with a new name and $90 million; Lilly acquired a pain company; and Gilgamesh reported positive PhIII results in MDD. Any one of these would have been a worthy headline for a day. To have them unveiled simultaneously was to open the cupboard to find forgotten supplies of dopamine.

And that's not all: In recent weeks there has been a slew of licensings and acquisitions in CNS, some from Big Pharmas that tend to keep a low profile in their neuroscience Business Development: Sanofi paid $470 million upfront for Vigil Neuroscience, GSK partnered with ABL Bio, paying $49.5 million upfront. As noted above, Lilly acquired SiteOne for its now semi-validated (by Vertex) Nav1.8 analgesic; and Biogen's departure from neuroscience is less binary than we once feared, as they partnered with City Therapeutics on a CNS-relevant RNAi technology.

The Psychedelic Space is Indeed at a Fundamental Inflection Point
The next issue (in early July) of NeuroPerspective will include our reviews of Parkinson's, Stroke, and our annual overview of Psychedelics. The Psychedelics area is in a particularly high-beta phase of volatile potential, just eight months after our Fall 2024 issue noted that a backlash to the hype was in full force after the Lykos/MDMA debacle at the FDA.

There are two critical datasets scheduled for release in the next month or two that will reset the industry calculus around the value of these highly anticipated treatment advances. Compass Pathways will unveil the results from the first PhIII trial of psilocybin, in Treatment-Resistant Depression: Compass has devoted vast resources to secularizing and routinizing psychedelic therapy, molding it into a semi-conventional, systematized drug development program geared to pass regulatory and investor muster. This was necessary if psychedelic therapy is ever to be something more than an ultra-boutique treatment option, even if some of the psychotherapeutic art that maximizes psychedelic efficacy had to be sacrificed along the way.

We are optimistic that this trial will be successful: if for some reason it were to fall short, that would presage a nuclear fiscal winter for Psychedelics, but we expect the opposite—that it will fuel a surge of interest in a viable treatment option. Soon thereafter, a substantial PhIIb study of 5-MeO-DMT in depression will be unblinded by Atai and Beckley Psytech, the most rigorous test thus far of a rapid-acting psychedelic. Atai is sufficiently optimistic about this dataset that they have already announced their acquisition of the roughly two-thirds of Beckley they do not already own, even though that agreement is contingent upon a positive outcome for the PhIIb.

Over 26% of the institutional investment in neurotherapeutics thus far in 2025 has been for Psychedelics companies; that share will expand still further if both these trials perform as we expect. As our friends at the estimable, indeed essential, information resource Psychedelic Alpha have written, “2025 is set to be a watershed year for the psychedelics field.”

Illogical Extrapolation from the Tiny to the Enormous
A recently published (JAMA Neurology) population-based study run by a Karolinska Institute team suggested that there could be factors in common underlying both Autism Spectrum Disorder and Parkinson's: they asserted that ASD increases the risk of PD fourfold, and speculated that PARK2 could constitute such a genetic common ground.

This caught our attention, but not in a good way. In looking more closely at the findings we found it noteworthy—but not credible—that the prevalence of ASD in this Swedish sample was reported as just 0.02%, far below the most recent US estimate of 3%, and even minuscule compared with a recent 1% prevalence estimate for Sweden. Secondly, with all due respect for a reported p value of .05, there were just 462 individuals with early-onset PD out of the 2.3 million subjects tracked for twenty-two years, and only 24 who also carried an Autism diagnosis. Such infinitesimally small cohorts provide a curiously skimpy basis for their broad-brush conclusion that there is a “potentially shared etiology between neurodevelopmental disorders and PD.”

2025 and a Flood of Clinical Data
Beyond the two datasets cited above, the next seven months will see a raft of fascinating datasets in a range of treatment indications, including trials from AbbVie, Actinogen, Alto, Autobahn, BMS, Cybin, Engrail, GSK/Alector, HMNC, Lundbeck, Noema, Neuphoria, Novo Nordisk, Reunion, Taysha, Vesper Bio, Takeda/Denali, and VistaGen.

At the very least, they will provide both information and temporary distraction from the societal and governmental tumult that seems currently unavoidable.

6/3/25
An Interim Note from NeuroPerspective

Source: https://www.linkedin.com/posts/harry-tracy-87396622_neurogram-6-3-25-activity-7335798449495306243-jB71?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAJoK6EBnIwCn0E2NHL-1bXmpN-YL5WhzPk

1.6B valuation set after merger...

ATAI Life Sciences Shares Jump Following Merger Announcement with Beckley Psytech

https://ih.advfn.com/market-news/article/11057/atai-life-sciences-shares-jump-following-merger-announcement-with-beckley-psytech

Programming ALERT ⚠️ Christian is going to be on the AdvisorShares.com podcast Live June 5th at 12.00 eastern time.

Spread the word!
Give ATAI some exposure!


.

The sector is heating 🔥 up and coming back to life Finally 🙌

Just the beginning here now! 💯👏

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

https://ih.advfn.com/stock-market/NASDAQ/atai-life-sciences-nv-ATAI/stock-news/96158659/atai-life-sciences-and-beckley-psytech-to-combine

after the first TLD hits in H2 all bets are off. These will all rise considerably.

Unexpected right now would be them or MNMD getting bought out. Which is feasible with good TLD at this point to scoop up IP.

Double Boost coming... ATAI will move up with positive news (coming soon) + Sector Boost- when the entire sector starts gaining traction everyone within it will rise 🌞

Honestly I think they're good too but im ready to expect the unexpected 😏.

Personally I don't think they have a need to RS. Not at this point. I understand you point but I think we're good.

Im thinking an R/S could be coming and it will be great!

The top 4 or 5 psychedelic stocks have Under 100m O/S but ATAI is Over 200m shares O/S .

Any thoughts?

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors

https://www.benzinga.com/markets/cannabis/25/05/45601096/ex-govt-foe-joins-trump-rfk-jr-s-hhs-to-lead-psychedelics-policy-what-it-means-for-investors?utm_source=articleShare

POLITICSLawyer Who Sued Federal Health Agency Over Marijuana Rescheduling Will Now Work There, With Focus On Psychedelics

https://www.marijuanamoment.net/lawyer-who-sued-federal-health-agency-to-release-marijuana-documents-now-works-there-with-focus-on-psychedelics/

This is huge for the sector. Lock your shares. This will now officially heat up. Wow.

Nice grab! Definitely a Winner 🏆 here!

Excellent timing. Don't forget to check out MindMed. They have 3 phase 3 trials right now as well.

I bought in at $1.70 and am optimistic for FDA approval and future growth.

Yes sir :P

Awesome and very thorough report 👏

Jefferies ATAI Review... look no further. Bullish.

https://www.pdffiller.com/jsfiller-desk10/?traceparent=00-07ed7164f15c9774bd00783077549229-fc1ccb08f076ac3e-00&flat_pdf_quality=high&isShareViaLink=1&requestHash=d89f179b33436ea1ff3d0219f9f6e1898c459312c390b43a4e073517365fe2a9&lang=en&projectId=1859669499&richTextFormatting=true&jsf-page-rearrange-v2=false&jsf-fake-edit-embedded=true&isSkipEditorLoadFrequency=true&jsf-probability-70=true&jsf-socket-io=false&jsf-edit-button=true&jsf-offline-mode=false&jsf-heading-bold=true&jsf-fake-edit-stream-editing=false&acc-share-button-in-editor=false&jsf-all-tools-tab=false&jsf-all-tools-tab-branch-b=false&isUseStaticImport=true&routeId=5c523af616f05f6263c9efcb018f6c64#b32cc6f86c3a418cba289aa5c2b9f3b6

You got that right... and it has begun... 📈

All signals GO!... ATAI still Extremely Undervalued at $2 Bucks!

Nice grab! ATAI is just warming up.
🔥

I am new to ATAI. Got in at the $1.70. I am enjoying the ride and appreciate your post.

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-data-part-2/

Whole sector is about to boom. Trend is already starting across the board.

Have you noticed Christian has become more actively posting on socials hinting at big things are imminent.

It's going to be a good ride. Many read out catalysts over the next 12 months. I agree it's wild no one is here.

Why so empty here? ATAI is about to go PARABOLIC! and this board is empty right now?
But I have a feeling people will be flooding in real soon. :)👍️😊 Only 24 followers

I agree 💯 we are very close now to a major move within the psychedelic sector.... FINALLY!!

Smart money is coming in ahead of some readouts in the sector. Going to be interesting over the next year. :)